Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$26.99
0.0%
$23.48
$12.21
$41.31
$793.27M-0.27492,955 shs517,706 shs
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
$21.45
-2.0%
$22.05
$15.47
$36.37
$748.91M1.2325,649 shs185,689 shs
Oculis Holding AG stock logo
OCS
Oculis
$17.65
-2.4%
$18.90
$10.79
$23.08
$789.85M0.2912,489 shs8,552 shs
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
$1.62
-4.1%
$1.69
$0.95
$10.24
$196.09M1.1851,622 shs228,544 shs
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
+3.01%+0.52%+18.32%+31.00%-26.95%
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
+1.53%-0.05%-3.99%+3.40%+7.15%
Oculis Holding AG stock logo
OCS
Oculis
+2.61%+1.29%-7.94%+0.22%+57.03%
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
-3.98%+1.50%-8.15%+6.96%-81.79%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
1.4151 of 5 stars
3.40.00.00.00.02.50.6
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
2.2607 of 5 stars
4.60.00.00.02.60.80.0
Oculis Holding AG stock logo
OCS
Oculis
1.5945 of 5 stars
3.53.00.00.00.00.00.6
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
0.5044 of 5 stars
0.05.00.00.00.00.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
2.80
Moderate Buy$47.1374.60% Upside
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
3.14
Buy$39.2983.15% Upside
Oculis Holding AG stock logo
OCS
Oculis
3.00
Buy$35.33100.19% Upside
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SXTC, OCS, ANAB, and AVBP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/24/2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$42.00 ➝ $80.00
7/22/2025
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$40.00
7/10/2025
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$33.00
6/24/2025
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$39.00 ➝ $44.00
6/24/2025
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$45.00
6/4/2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$22.00 ➝ $38.00
5/29/2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$40.00
5/28/2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$54.00 ➝ $90.00
5/20/2025
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$40.00
5/14/2025
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$39.00 ➝ $40.00
5/9/2025
Oculis Holding AG stock logo
OCS
Oculis
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$28.00 ➝ $33.00
(Data available from 7/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$91.28M8.69N/AN/A$2.33 per share11.58
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
N/AN/AN/AN/A$7.65 per shareN/A
Oculis Holding AG stock logo
OCS
Oculis
$780K987.95N/AN/A$1.91 per share9.24
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
$1.93M97.39N/AN/A$243.66 per share0.01
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$145.23M-$4.85N/AN/AN/A-125.70%-282.47%-30.79%8/4/2025 (Estimated)
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
-$80.49M-$3.77N/AN/AN/AN/A-49.21%-46.61%8/13/2025 (Estimated)
Oculis Holding AG stock logo
OCS
Oculis
-$97.43M-$2.64N/AN/AN/A-13,788.70%-92.95%-70.03%8/26/2025 (Estimated)
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
-$3.10MN/A0.00N/AN/AN/AN/AN/A

Latest SXTC, OCS, ANAB, and AVBP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
-$0.70N/AN/AN/AN/AN/A
8/4/2025Q2 2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$1.47N/AN/AN/A$11.55 millionN/A
5/12/2025Q1 2025
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
-$0.66-$1.90-$1.24-$1.90N/AN/A
5/8/2025Q1 2025
Oculis Holding AG stock logo
OCS
Oculis
-$0.51-$0.77-$0.26-$0.77$0.22 million$0.32 million
5/5/2025Q1 2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$1.30-$1.28+$0.02-$1.28$15.27 million$27.77 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/AN/AN/AN/AN/A
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
N/AN/AN/AN/AN/A
Oculis Holding AG stock logo
OCS
Oculis
N/AN/AN/AN/AN/A
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/A
8.25
8.25
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
N/A
14.34
14.34
Oculis Holding AG stock logo
OCS
Oculis
N/A
4.79
4.79
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/A
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
9.48%
Oculis Holding AG stock logo
OCS
Oculis
22.30%
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
5.02%

Insider Ownership

CompanyInsider Ownership
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
33.50%
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
18.58%
Oculis Holding AG stock logo
OCS
Oculis
N/A
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
3.95%
CompanyEmployeesShares OutstandingFree FloatOptionable
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
10029.38 million19.54 millionOptionable
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
4034.21 million27.86 millionN/A
Oculis Holding AG stock logo
OCS
Oculis
243.66 millionN/ANot Optionable
China SXT Pharmaceuticals, Inc. stock logo
SXTC
China SXT Pharmaceuticals
90116.03 million111.45 millionNot Optionable

Recent News About These Companies

China SXT Pharmaceuticals, Inc. (SXTC) - Yahoo Finance
China SXT Pharmaceuticals Inc Ordinary Shares
China SXT Pharmaceuticals regains compliance with Nasdaq
China SXT Pharmaceuticals Inc trading resumes
China SXT Pharmaceuticals Inc trading halted, volatility trading pause
China SXT Pharmaceuticals Inc trading halted, news pending
china sxt pharmaceuticals - SXTC

New MarketBeat Followers Over Time

Media Sentiment Over Time

AnaptysBio stock logo

AnaptysBio NASDAQ:ANAB

$26.99 -0.01 (-0.04%)
Closing price 04:00 PM Eastern
Extended Trading
$26.96 -0.03 (-0.11%)
As of 05:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

ArriVent BioPharma stock logo

ArriVent BioPharma NASDAQ:AVBP

$21.45 -0.44 (-2.01%)
Closing price 04:00 PM Eastern
Extended Trading
$21.46 +0.02 (+0.07%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Oculis stock logo

Oculis NASDAQ:OCS

$17.65 -0.44 (-2.43%)
Closing price 04:00 PM Eastern
Extended Trading
$17.52 -0.13 (-0.74%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

China SXT Pharmaceuticals stock logo

China SXT Pharmaceuticals NASDAQ:SXTC

$1.62 -0.07 (-4.14%)
Closing price 03:59 PM Eastern
Extended Trading
$1.66 +0.04 (+2.78%)
As of 06:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.